Avanafil

SECTION 2: Hazards identification

Ingredient(s) with unknown acute toxicity

16.2% (oral), 29.7% (dermal), 55.1% (inhalation)

Signal word

Warning

Hazard statements

Flammable liquid and vapor. Harmful if inhaled. May cause drowsiness or dizziness. Suspected of causing cancer.

Prevention

Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Wear protective gloves, protective clothing and eye or face protection. Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. Use only outdoors or in a well-ventilated area. Avoid breathing vapor.

Response

IF exposed or concerned Get medical advice or attention. IF INHALED Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER or doctor if you feel unwell. IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin with water.

Storage

Store locked up. Store in a well-ventilated place. Keep container tightly closed.

Disposal

Dispose of contents and container in accordance with all local, regional, national and international regulations.

Supplemental label elements

Sanding and grinding dusts may be harmful if inhaled. Repeated exposure to high vapor concentrations may cause irritation of the respiratory system and permanent brain and nervous system damage. Inhalation of vapor/aerosol concentrations above the recommended exposure limits causes headaches, drowsiness and nausea and may lead to unconsciousness or death. Avoid contact with skin and clothing. Wash thoroughly after handling. Emits toxic fumes when heated.

2.3 Other hazards

May form explosive peroxides. Hazardous reactions or instability may occur under certain conditions of storage or use. Prolonged or repeated contact may dry skin and cause irritation.

2.1 Classification of the substance or mixture

ACUTE TOXICITY (inhalation) - Category 4 CARCINOGENICITY - Category 2 SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) (Narcotic effects) - Category 3 Percentage of the mixture consisting of ingredient(s) of unknown acute toxicity: 16.2% (oral), 29.7% (dermal), 55.1% (inhalation)